SEC Form 4 · accession 0001654954-17-004110
NAVIDEA BIOPHARMACEUTICALS, INC. · NAVB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jed Latkin
Officer — COO and CFO
Period of report
May 4, 2017
Accepted (ET)
May 5, 2017 · 1:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000810509
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | — | May 4, 2017 | A | 1,000,000 | A | — | May 4, 2027 | Common Stock | 1,000,000 | 1,065,000 | D |
Explanation of responses
- F1333,334 options with a strike price of $0.65 will be exercisable on or after 5/4/2017, so long as the closing market price of the underlying common stock equals or exceeds $0.85 per share; 333,333 options with a strike price of $0.75 will be exercisable on or after 12/31/2017, so long as the closing market price of the underlying common stock equals or exceeds $1.00 per share; and 333,333 options with a strike price of $1.00 will be exercisable on or after 12/31/2018, so long as the closing market price of the underlying common stock equals or exceeds $1.25 per share.